Merck seeks new formulations boost for Noxafil
This article was originally published in Scrip
Executive Summary
Merck says it is looking to new formulations of the antifungal Noxafil (posaconazole) oral suspension to address treatment limitations observed by doctors for immunosuppressed patients susceptible to invasive fungal infections (IFI).